The value of observational registry studies for the next infectious disease emergency

Jonathon W. Senefeld; Peter Marks; Arturo Casadevall; Michael J. Joyner

doi:10.1128/mbio.02565-23

The value of observational registry studies for the next infectious disease emergency

Jonathon W. Senefeld, Peter Marks, Arturo Casadevall, Michael J. Joyner

Anesthesiology

Research output: Contribution to journal › Review article › peer-review

Abstract

During infectious disease emergencies, it may be necessary to deploy new therapies without conclusive evidence for their effectiveness. During the SARS-CoV-2 pandemic, several countries used registries to track the use of COVID-19 convalescent plasma (CCP). Those registries provided evidence that CCP was effective when used early and with high titer.

Original language	English (US)
Journal	mBio
Volume	14
Issue number	6
DOIs	https://doi.org/10.1128/mbio.02565-23
State	Published - Dec 2023

Keywords

clinical trials
coronavirus
neutralizing antibodies

ASJC Scopus subject areas

Microbiology
Virology

Access to Document

10.1128/mbio.02565-23

Cite this

@article{4e4ca0f399864dd38620ab94448e8862,

title = "The value of observational registry studies for the next infectious disease emergency",

abstract = "During infectious disease emergencies, it may be necessary to deploy new therapies without conclusive evidence for their effectiveness. During the SARS-CoV-2 pandemic, several countries used registries to track the use of COVID-19 convalescent plasma (CCP). Those registries provided evidence that CCP was effective when used early and with high titer.",

keywords = "clinical trials, coronavirus, neutralizing antibodies",

author = "Senefeld, {Jonathon W.} and Peter Marks and Arturo Casadevall and Joyner, {Michael J.}",

year = "2023",

month = dec,

doi = "10.1128/mbio.02565-23",

language = "English (US)",

volume = "14",

journal = "mBio",

issn = "2161-2129",

publisher = "American Society for Microbiology",

number = "6",

}

TY - JOUR

T1 - The value of observational registry studies for the next infectious disease emergency

AU - Senefeld, Jonathon W.

AU - Marks, Peter

AU - Casadevall, Arturo

AU - Joyner, Michael J.

PY - 2023/12

Y1 - 2023/12

N2 - During infectious disease emergencies, it may be necessary to deploy new therapies without conclusive evidence for their effectiveness. During the SARS-CoV-2 pandemic, several countries used registries to track the use of COVID-19 convalescent plasma (CCP). Those registries provided evidence that CCP was effective when used early and with high titer.

AB - During infectious disease emergencies, it may be necessary to deploy new therapies without conclusive evidence for their effectiveness. During the SARS-CoV-2 pandemic, several countries used registries to track the use of COVID-19 convalescent plasma (CCP). Those registries provided evidence that CCP was effective when used early and with high titer.

KW - clinical trials

KW - coronavirus

KW - neutralizing antibodies

UR - http://www.scopus.com/inward/record.url?scp=85182883942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85182883942&partnerID=8YFLogxK

U2 - 10.1128/mbio.02565-23

DO - 10.1128/mbio.02565-23

M3 - Review article

C2 - 37937981

AN - SCOPUS:85182883942

SN - 2161-2129

VL - 14

JO - mBio

JF - mBio

IS - 6

ER -

The value of observational registry studies for the next infectious disease emergency

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this